The global biopsy device market accounted for USD 2.29 billion in 2023 and is expected to reach at USD 4.89 billion by 2034 with a CAGR of 7.13% during the forecast period 2024-2034. The factors that will propel the market expansion are the rising incidence of cancer, improvements in biopsy technologies, the growing preference for minimally invasive procedures, technological advancements in imaging modalities, and increasing awareness and programs for screening.
Globally, cancer continues to be one of the most common causes of death. The need for biopsies to diagnose, stage, and identify cancer early is growing along with the global increase in cancer incidence. Biopsy instruments are essential for harvesting tissue samples for precise diagnosis and formulating the right course of treatment. For instance, Becton, Dickinson and Company announced in January 2022 that it was acquiring Velano Vascular, a business that specialized in streamlining blood collection procedures.
By product, the needle-based biopsy guns segment accounted for the highest revenue-grossing segment in the global biopsy device market in 2023 owing to the increasing adoption of minimally invasive biopsy techniques, advancements in needle-based biopsy gun technology, and the rising prevalence of cancer worldwide, which necessitates accurate and efficient tissue sampling for diagnosis and treatment planning. For instance, Boston Scientific's EXALT Model B single-use bronchoscope was approved by the FDA in March 2022. Additionally, the biopsy needles segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for biopsy procedures, advancements in needle technology such as the development of finer gauge needles for improved tissue sampling, and the rising prevalence of cancer and other chronic diseases requiring frequent diagnostic biopsies.
By application, the medical diagnosis segment accounted for the highest revenue-grossing segment in the global biopsy device market in 2023 and is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for early and accurate diagnosis of various diseases, including cancer, infectious diseases, and autoimmune disorders, coupled with advancements in diagnostic technologies and the expanding scope of medical imaging modalities. For instance, Cook Medical launched the Beacon Tip TorpedoTM for percutaneous nephrolithotomy (PCNL) in February 2022.
By end-user, the hospital's segment accounted for the highest revenue-grossing segment in the global biopsy device market in 2023 owing to the increasing adoption of biopsy procedures for diagnostic purposes, the growing prevalence of cancer and other chronic diseases necessitating tissue sampling, and the expanding healthcare infrastructure, leading to enhanced accessibility to advanced medical technologies in hospital settings. For instance, DTR Medical Ltd.'s Vacuum Assisted Breast Biopsy System (VABBS) was granted CE Mark clearance in 2022. Additionally, the diagnostic centers segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for specialized diagnostic services, the rising prevalence of chronic diseases requiring accurate diagnosis, and the growing trend towards outsourcing diagnostic procedures to specialized facilities.
North American region is anticipated to have the highest revenue share during the forecast period owing to the advanced healthcare infrastructure, increasing prevalence of cancer and chronic diseases, adoption of innovative biopsy technologies, and favorable reimbursement policies. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapidly expanding healthcare infrastructure, rising awareness about early disease detection, increasing healthcare expenditure, and growing prevalence of cancer and other chronic diseases. For instance, TransMed7, LLC announced in August 2022 that a clinical case using the commercial manufacturing version of a Heron XPS gadget was the "First in Human."
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Globally, cancer continues to be one of the most common causes of death. The need for biopsies to diagnose, stage, and identify cancer early is growing along with the global increase in cancer incidence. Biopsy instruments are essential for harvesting tissue samples for precise diagnosis and formulating the right course of treatment. For instance, Becton, Dickinson and Company announced in January 2022 that it was acquiring Velano Vascular, a business that specialized in streamlining blood collection procedures.
By product, the needle-based biopsy guns segment accounted for the highest revenue-grossing segment in the global biopsy device market in 2023 owing to the increasing adoption of minimally invasive biopsy techniques, advancements in needle-based biopsy gun technology, and the rising prevalence of cancer worldwide, which necessitates accurate and efficient tissue sampling for diagnosis and treatment planning. For instance, Boston Scientific's EXALT Model B single-use bronchoscope was approved by the FDA in March 2022. Additionally, the biopsy needles segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for biopsy procedures, advancements in needle technology such as the development of finer gauge needles for improved tissue sampling, and the rising prevalence of cancer and other chronic diseases requiring frequent diagnostic biopsies.
By application, the medical diagnosis segment accounted for the highest revenue-grossing segment in the global biopsy device market in 2023 and is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for early and accurate diagnosis of various diseases, including cancer, infectious diseases, and autoimmune disorders, coupled with advancements in diagnostic technologies and the expanding scope of medical imaging modalities. For instance, Cook Medical launched the Beacon Tip TorpedoTM for percutaneous nephrolithotomy (PCNL) in February 2022.
By end-user, the hospital's segment accounted for the highest revenue-grossing segment in the global biopsy device market in 2023 owing to the increasing adoption of biopsy procedures for diagnostic purposes, the growing prevalence of cancer and other chronic diseases necessitating tissue sampling, and the expanding healthcare infrastructure, leading to enhanced accessibility to advanced medical technologies in hospital settings. For instance, DTR Medical Ltd.'s Vacuum Assisted Breast Biopsy System (VABBS) was granted CE Mark clearance in 2022. Additionally, the diagnostic centers segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for specialized diagnostic services, the rising prevalence of chronic diseases requiring accurate diagnosis, and the growing trend towards outsourcing diagnostic procedures to specialized facilities.
North American region is anticipated to have the highest revenue share during the forecast period owing to the advanced healthcare infrastructure, increasing prevalence of cancer and chronic diseases, adoption of innovative biopsy technologies, and favorable reimbursement policies. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapidly expanding healthcare infrastructure, rising awareness about early disease detection, increasing healthcare expenditure, and growing prevalence of cancer and other chronic diseases. For instance, TransMed7, LLC announced in August 2022 that a clinical case using the commercial manufacturing version of a Heron XPS gadget was the "First in Human."
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Product, Application, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
Segmentation: Biopsy Device Market Report 2023 - 2034
Biopsy Device Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Needle-based Biopsy Guns
- Vacuum-assisted Biopsy (VAB) Devices
- Fine Needle Aspiration Biopsy (FNAB) Devices
- Core Needle Biopsy (CNB) devices
- Biopsy Guidance Systems
- Manual
- Robotic
- Biopsy Needles
- Disposable
- Reusable
- Biopsy Forceps
- General Biopsy Forceps
- Hot Biopsy Forceps
- Others
- Brushes
- Curettes
- Punches
Biopsy Device Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Medical Diagnosis
- Scientific Research
Biopsy Device Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Hospital
- Specialized Oncology Centres
- Diagnostic Centers
- Research Institutes
Biopsy Device Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Biopsy Device Market: Product Estimates & Trend Analysis
8. Biopsy Device Market: Application Estimates & Trend Analysis
9. Biopsy Device Market: End-User Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Biopsy Device Market
12. Europe Global Biopsy Device Market
13. Asia Pacific Global Biopsy Device Market
14. Latin America Global Biopsy Device Market
15. MEA Global Biopsy Device Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Becton
- Dickinson and Company
- Medtronic plc
- Boston Scientific Corporation
- C. R. Bard Inc. (acquired by BD)
- Hologic Inc.
- Cook Medical LLC
- Olympus Corporation
- Fujifilm Holdings Corporation
- Cardinal Health Inc.
- Danaher Corporation (acquired Cepheid)
- Leica Biosystems Nussloch GmbH (part of Danaher Corporation)
- Argon Medical Devices Inc. (part of BD)
- INRAD Inc.
- DTR Medical Ltd.
- Scion Medical Technologies LLC.
